378 related articles for article (PubMed ID: 28427515)
1. FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Porta R; Borea R; Coelho A; Khan S; Araújo A; Reclusa P; Franchina T; Van Der Steen N; Van Dam P; Ferri J; Sirera R; Naing A; Hong D; Rolfo C
Crit Rev Oncol Hematol; 2017 May; 113():256-267. PubMed ID: 28427515
[TBL] [Abstract][Full Text] [Related]
2. Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC; Ronca R; Presta M; Giacomini A
Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
[TBL] [Abstract][Full Text] [Related]
3. Targeting the fibroblast growth factor receptor family in cancer.
Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
[TBL] [Abstract][Full Text] [Related]
4. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
[No Abstract] [Full Text] [Related]
5. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
6. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
[TBL] [Abstract][Full Text] [Related]
7. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
8. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
9. Recent developments and advances of FGFR as a potential target in cancer.
Xue WJ; Li MT; Chen L; Sun LP; Li YY
Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
11. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
De Luca A; Esposito Abate R; Rachiglio AM; Maiello MR; Esposito C; Schettino C; Izzo F; Nasti G; Normanno N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962091
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
Brooks AN; Kilgour E; Smith PD
Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
[TBL] [Abstract][Full Text] [Related]
13. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
14. New Insights in the Interaction of FGF/FGFR and Steroid Receptor Signaling in Breast Cancer.
Pérez Piñero C; Giulianelli S; Lamb CA; Lanari C
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34977930
[TBL] [Abstract][Full Text] [Related]
15. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
Chandana SR; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
[TBL] [Abstract][Full Text] [Related]
16. Targeting mutant fibroblast growth factor receptors in cancer.
Greulich H; Pollock PM
Trends Mol Med; 2011 May; 17(5):283-92. PubMed ID: 21367659
[TBL] [Abstract][Full Text] [Related]
17. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Ang C
J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.
Kim B; Wang S; Lee JM; Jeong Y; Ahn T; Son DS; Park HW; Yoo HS; Song YJ; Lee E; Oh YM; Lee SB; Choi J; Murray JC; Zhou Y; Song PH; Kim KA; Weiner LM
Oncogene; 2015 Feb; 34(9):1083-93. PubMed ID: 24662823
[TBL] [Abstract][Full Text] [Related]
19. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Vanni I; Boccardo S; Alama A; Grossi F
Expert Opin Investig Drugs; 2017 May; 26(5):551-561. PubMed ID: 28388262
[TBL] [Abstract][Full Text] [Related]
20. Targeting fibroblast growth factor receptor pathway in breast cancer.
Criscitiello C; Esposito A; De Placido S; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
